UBS Sticks to Their Hold Rating for Astellas Pharma (ALPMF)
In a report released today, from UBS maintained a Hold rating on Astellas Pharma, with a price target of Yen2,350.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
In addition to UBS, Astellas Pharma also received a Hold from TipRanks – OpenAI’s OpenAI Drug Manufacturers – General in a report issued on January 25. However, on the same day, TipRanks – xAI reiterated a Buy rating on Astellas Pharma (Other OTC: ALPMF).
ALPMF market cap is currently Yen4003.1B and has a P/E ratio of 32.44.
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.